Scholarlink

<p>Advances in targeted therapies for newly diagnosed primary central nervous system lymphoma (PCNSL) were a key highlight at the 2025 ASH Annual Meeting. While high-dose methotrexate (HD-MTX) remains the cornerstone of PCNSL treatment, the integration of BTK inhibitors, immunomodulators, and novel agents—such as selinexor and anti-PD-1 antibodies—is reshaping the first-line management paradigm. These emerging combinations are improving response rates and survival, paving the way for more effective strategies. Here, we provide a timely synthesis of these pivotal updates presented at ASH 2025.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advances in first-line treatment for primary central nervous system lymphoma: highlights from the 2025 ASH annual meeting

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月9日

查看全文
  • Rong Wei,
  • Shenmiao Yang

摘要

Advances in targeted therapies for newly diagnosed primary central nervous system lymphoma (PCNSL) were a key highlight at the 2025 ASH Annual Meeting. While high-dose methotrexate (HD-MTX) remains the cornerstone of PCNSL treatment, the integration of BTK inhibitors, immunomodulators, and novel agents—such as selinexor and anti-PD-1 antibodies—is reshaping the first-line management paradigm. These emerging combinations are improving response rates and survival, paving the way for more effective strategies. Here, we provide a timely synthesis of these pivotal updates presented at ASH 2025.